Bionano Genomics (BNGO) Operating Expenses (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Operating Expenses data on file, last reported at $11.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 2.23% year-over-year to $11.1 million; the trailing twelve-month figure through Mar 2026 stood at $46.3 million (down 43.45% YoY), and the FY2025 full-year result was $46.5 million, down 55.42% from the prior year.
• Operating Expenses retreated to $11.1 million in Q1 2026, from $11.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $116.0 million in Q3 2023 to a low of $11.1 million in Q1 2026.
• A 5-year average of $30.9 million and a median of $30.8 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 241.48% in 2023 and sank 69.43% in 2024, its largest moves.
• Tracing BNGO's Operating Expenses over 5 years: stood at $39.3 million in 2022, then sank by 30.36% to $27.4 million in 2023, then slumped by 43.93% to $15.4 million in 2024, then slipped by 22.29% to $11.9 million in 2025, then retreated by 6.59% to $11.1 million in 2026.
• Business Quant data shows BNGO's Operating Expenses at $11.1 million in Q1 2026, $11.9 million in Q4 2025, and $11.9 million in Q3 2025.